Abstract
Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 869-871 |
Number of pages | 3 |
Journal | Journal of Drugs in Dermatology |
Volume | 13 |
Issue number | 7 |
State | Published - Jul 2014 |
ASJC Scopus subject areas
- Dermatology